Department of Haematology, Erasmus Medical Center, Rotterdam;
Department of Haematology, Erasmus Medical Center, Rotterdam.
Clin Chem. 2016 Dec;62(12):1639-1646. doi: 10.1373/clinchem.2016.261248. Epub 2016 Sep 27.
Levels of hemostasis factors vary between and within individuals as a result of genetic and environmental factors and analytical variation of the assays. The current state of the art for defining analytical precision requirements for analytical testing is based on this between- and within-individual (biological) variation. However, information on biological variation in hemostasis variables is still limited.The aim of this study was to determine the biological variation of coagulation variables involved in thrombosis and bleeding to provide a recommendation for performance specifications and to assess whether hemostasis assays fulfill the recommendation.
We performed a longitudinal study by repeated blood sampling (in total 13 times over a 1-year period) in 40 healthy individuals and measured prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, antithrombin, factor VIII, factor IX, von Willebrand factor (VWF), protein C, and protein S. We evaluated the effect of the biological variation on parameters of analytical variation and propose required performance specifications.
Biological variation was highly different for various hemostasis variables: the within-subject variation ranged from 2.6% (PT) to 25.6% [VWF collagen binding (CB) activity], the between-subject variation varied from 4.1% (PT) to 31.2% (VWF:ristocetin cofactor acitivity), and the assay variation from 1.3% (PT) to 12.9% (VWF:CB).
With the reagents and analyzers used in this study, most of the hemostasis tests variables fulfill the current quality criteria for diagnosis and monitoring of routine hemostasis assays.
由于遗传和环境因素以及分析检测的变化,止血因子的水平在个体之间和个体内部存在差异。目前,定义分析测试分析精度要求的最新技术是基于这种个体内和个体间(生物学)的变化。然而,关于止血变量生物学变异的信息仍然有限。本研究的目的是确定参与血栓形成和出血的凝血变量的生物学变异,为性能规范提供建议,并评估止血检测是否符合建议。
我们通过对 40 名健康个体进行重复采血(在 1 年内共采血 13 次)进行了一项纵向研究,并测量了凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原、抗凝血酶、VIII 因子、IX 因子、血管性血友病因子(VWF)、蛋白 C 和蛋白 S。我们评估了生物学变异对分析变异参数的影响,并提出了所需的性能规范。
各种止血变量的生物学变异差异很大:个体内变异范围为 2.6%(PT)至 25.6%[VWF 胶原结合(CB)活性],个体间变异范围为 4.1%(PT)至 31.2%(VWF:瑞斯托霉素辅因子活性),检测变异范围为 1.3%(PT)至 12.9%(VWF:CB)。
使用本研究中的试剂和分析仪,大多数止血测试变量都符合当前用于诊断和监测常规止血检测的质量标准。